Lates News

The U.S. Food and Drug Administration has requested Sarepta Therapeutics Inc. to suspend the distribution of Elevidys. The company has been asked to halt the clinical trials of Elevidys. The study participants may face unreasonable risks. The company has refused to voluntarily stop shipping Elevidys.